Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Cash from Operations (2021 - 2026)

Nuvectis Pharma has reported Cash from Operations over the past 6 years, most recently at 6511000.0 for Q1 2026.

  • Quarterly results put Cash from Operations at 6511000.0 for Q1 2026, down 55.99% from a year ago — trailing twelve months through Mar 2026 was 18346000.0 (down 52.08% YoY), and the annual figure for FY2025 was 16009000.0, down 30.72%.
  • Cash from Operations reached 6511000.0 in Q1 2026 per NVCT's latest filing, down from 3974000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2404000.0 in Q3 2024 and bottomed at 6511000.0 in Q1 2026.
  • Median Cash from Operations over the past 5 years was 3850000.0 (2023), compared with a mean of 3781176.47.
  • The largest annual shift saw Cash from Operations crashed 229.52% in 2022 before it skyrocketed 35.97% in 2024.
  • Over 5 years, Cash from Operations stood at 3516000.0 in 2022, then fell by 9.5% to 3850000.0 in 2023, then soared by 35.97% to 2465000.0 in 2024, then tumbled by 61.22% to 3974000.0 in 2025, then plummeted by 63.84% to 6511000.0 in 2026.
  • Business Quant data shows Cash from Operations for NVCT at 6511000.0 in Q1 2026, 3974000.0 in Q4 2025, and 4494000.0 in Q3 2025.